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ABSTRACT 
We previously generated mito-mice-tRNALys7731 as a model for primary prevention of 
mitochondrial diseases. These mice harbour a G7731A mtDNA mutation in the tRNALys 
gene, but express only muscle weakness and short body length by four months. Here, 
we examined the effects of their aging on metabolic and histologic features. Unlike 
young mito-mice-tRNALys7731, aged mito-mice-tRNALys7731 developed muscle atrophy, 
renal failures, and various metabolic abnormalities, such as lactic acidosis and anemia, 
characteristic of patients with mitochondrial diseases. These observations provide 
convincing evidence that the respiration defects induced by high G7731A mtDNA 
levels cause these late-onset disorders that are relevant to mitochondrial diseases.  
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Abbreviations: 
mtDNA, mitochondrial DNA; ΔmtDNA, mtDNA with large-scale deletions; CPEO, 
chronic progressive external ophthalmoplegia; MERRF, myoclonic epilepsy with 
ragged red fibers; MELAS, mitochondrial myopathy, encephalopathy, lactic acidosis, 
and stroke-like episodes syndrome; COX, cytochrome c oxidase; RRFs, ragged red 
fibers; SDH, succinate dehydrogenase. 
 
Highlight:  
1: Mito-mice with a G7731A mtDNA mutation in the tRNALys gene were used as 
MERRF models.  
2: Aging effects were compared between mito-mice with low and high G7731A 
mtDNA levels.  
3. Only aged mito-mice with high G7731A mtDNA levels developed late-onset 
disorders. 
4. The late-onset disorders were due to the respiration defects caused by G7731A 
mtDNA.  
5. More than 85% G7731A mtDNA would be required to induce RRFs in the mito-mice.  
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1. Introduction 
The accumulation of mitochondrial DNA (mtDNA) with pathogenic mutations is 
proposed to be closely associated with mitochondrial diseases, normal aging, and age-
associated disorders, including diabetes, because of its induction of significant 
respiration defects [1–3]. Three most prevalent mitochondrial diseases are chronic 
progressive external ophthalmoplegia (CPEO), due to mtDNA with large-scale 
deletions (ΔmtDNA); myoclonic epilepsy with ragged-red fibers (MERRF), due to 
single-point mutations in the tRNALys gene; and mitochondrial myopathy, 
encephalopathy, lactic acidosis, and stroke-like episodes syndrome (MELAS), due to 
single-point mutations in the tRNALeu(UUR) gene [1–3]. Subsequent studies [4–6] have 
proved the pathogenicities of these mtDNA mutations by inducing respiration defects 
after the transfer of patient-derived mutated mtDNA into mtDNA-less human cells. 
However, it has not been established unequivocally whether the respiration defects due 
to the accumulation of mtDNA with pathogenic mutations in the tissues actually induce 
the various clinical phenotypes observed in patients with mitochondrial diseases or with 
age-associated disorders. 
This issue was resolved in part by our previous studies [7–11], in which we generated 
transmitochondrial mice (mito-mice) carrying exogenously introduced mouse mtDNA 
with mutations orthologous to those found in patients with mitochondrial diseases. For 
example, mito-mice-Δ, which harbored mouse ΔmtDNA and therefore corresponded to 
disease models for CPEO, simultaneously expressed respiration defects, which were 
induced by accumulated ΔmtDNA, and disease phenotypes corresponding to those of 
CPEO in humans [7, 8]. Therefore, experiments in mito-mice could provide convincing 
evidence that the respiration defects due to mtDNA mutations regulate clinical 
abnormalities relevant to mitochondrial diseases or age-associated disorders. 
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We recently generated mito-mice-tRNALys7731, which harbour mtDNA that contain a 
pathogenic G7731A mutation in the tRNALys gene (G7731A mtDNA), as a model for 
primary prevention of mitochondrial diseases [12]. Because a G8328A mutation 
orthologous to the mouse G7731A mutation occurs in patients with mitochondrial 
diseases [13, 14], mito-mice-tRNALys7731 can be used as prospective models for diseases 
that, like MERRF, are caused by mutations in the mitochondrial tRNALys gene. Young 
mito-mice-tRNALys7731 with high levels of G7731A mtDNA expressed respiration 
defects and the resultant phenotypic features characteristic of mitochondrial diseases, 
such as short body length and muscle weakness, but they did not exhibit ragged red 
fibers (RRFs) or other traits seen in patients with mitochondrial diseases [12]. 
Here, to compare the effects of aging on the expression of phenotypes characteristic of 
mitochondrial diseases and age-associated disorders, we used aged mito-mice-
tRNALys7731 that share the same nuclear background but carry either low or high levels 
of G7731A mtDNA. 
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2. Materials and Methods 
Mice. Inbred B6 mice were obtained from CLEA Japan. Mito-mice-tRNALys7731 were 
generated in our previous work [12]. Animal experiments were performed in accordance 
with protocols approved by the Experimental Animal Committee of the University of 
Tsukuba, Japan (approval number, 14243). 
Genotyping of mtDNA. To detect the G7731A mutation, a 130-bp fragment containing 
the 7731 site was PCR-amplified by using the nucleotide sequences from 7633 to 7653 
(5′-GCCCATTGTCCTAGAAATGGT-3′) and 7762 to 7732 (5′-
ACTATGGAGATTTTAAGGTCTCTAACTTTAA-3′) as oligonucleotide primers. The 
G7731A mutation creates a restriction site for DraI and generates 96- and 34-bp 
fragments on DraI digestion of PCR products. The restriction fragments were separated 
by electrophoresis in a 3% agarose gel. For quantification of G7731A mtDNA, we used 
ImageJ (Rasband, WS., Image J, U.S. National Institutes of Health, Bethesda, Maryland, 
USA, http://imagej.nih.gov/ij/, 1997–2014) software. 
Histopathologic analyses. Formalin-fixed, paraffin-embedded sections (thickness, 5 
µm) were stained with hematoxylin and eosin (H&E) to identify features characteristic 
of renal failures. Cryosections (thickness, 10 µm) of skeletal muscle were stained with 
modified Gomori trichrome for histopathologic analysis to identify RRFs. Cryosections 
(thickness, 10 µm) of renal tissues were prepared, and histologic analyses of COX and 
succinate dehydrogenase activities were performed as described previously [15]. 
Grip strength test. Muscle strength was estimated by using a Grip Strength Meter 
(Columbus Instruments, Columbus, USA); three sequential trials were performed on 
each mouse bilaterally. 
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Measurement of blood glucose, lactate, and BUN. To determine fasting blood lactate 
and glucose concentrations, peripheral blood was collected from the tail veins of mice 
after food had been withheld overnight. Glucose (1.5 g/kg body weight) was 
administered orally, blood was collected 15-120 minutes after glucose administration, 
and lactate and glucose concentrations were measured with an automatic blood lactate 
meter (Lactate Pro 2; Arkray, Kyoto, Japan) and glucose meter (Dexter ZII; Bayer, 
Leverkusen, Germany), respectively. BUN was measured with a Urea N B test (Wako 
Pure Chemical, Osaka, Japan) in accordance with the manufacturer’s protocol. 
Measurement of hematocrit. To determine hematocrit, capillary blood samples were 
obtained from each mouse by using heparinized capillary tubes, which then were 
centrifuged at 10,500 × g for 5 min. Packed cell volumes were measured by using a 
hematocrit reader. 
Statistical analysis. Data are presented as mean ± SD and were analysed by using 
Student’s t test; P values less than 0.05 were considered significant. Excel software was 
used for all statistical analysis. 
 
3. Results 
3.1. Late-onset metabolic abnormalities in aged mito-mice-tRNALys7731  
We used aged (26-month-old) male mito-mice-tRNALys7731 with low (<5%) or high 
(70% to 75%) levels of G7731A mtDNA in their tails at 4 weeks after birth and age- 
and sex-matched B6 mice (negative controls). We first evaluated body length (Fig. 1A) 
and muscle strength (Fig. 1B), because abnormalities in these phenotypes are expressed 
in young (4-month-old) mito-mice-tRNALys7731 [12] and can be examined without 
killing the mice. Short body length (Fig. 1A) and muscle weakness (Fig. 1B), which are 
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closely associated with the clinical abnormalities caused by the orthologous G8328A 
mutation in the human mitochondrial tRNALys gene [13, 14], occurred exclusively in 
mito-mice-tRNALys7731 with high levels of G7731A mtDNA. These results are 
consistent with our previous findings obtained from young mito-mice-tRNALys7731 [12]. 
We then examined various metabolic parameters relevant to mitochondrial diseases. 
Whereas these features were normal in our young mito-mice-tRNALys7731 [12], we 
expected that abnormalities in these parameters would be expressed as late-onset 
disorders as the mito-mice-tRNALys7731 aged. Unlike aged B6 mice and aged mito-mice-
tRNALys7731 with low levels of G7731A mtDNA, aged mito-mice-tRNALys7731 with high 
levels of G7731A mtDNA exclusively had low hematocrit values (Fig. 1C), lactic 
acidosis (Fig. 1D), and increased levels of BUN in the peripheral blood (Fig. 1E). In 
contrast, although patients with mitochondrial diseases sometimes demonstrate 
mitochondrial diabetes [1–3], neither group of aged mito-mice-tRNALys7731 manifested 
hyperglycemia (Fig. 1F). Therefore, except for hyperglycemia, the metabolic 
abnormalities seen in patients with mitochondrial diseases were expressed as late-onset 
disorders in aged mito-mice-tRNALys7731 with high levels of G7731A mtDNA. 
3.2. Lifespan and tissue abnormalities in euthanized moribund mito-mice-tRNALys7731  
We then assessed the lifespans of mito-mice-tRNALys7731 and the tissue abnormalities in 
euthanized moribund mice. The median survival times in B6 mice and in mito-mice-
tRNALys7731 with low or high levels of G7731A mtDNA were 26, 28, and 27 months, 
respectively (Fig. 2). Thus, median survival times did not differ significantly between 
mito-mice-tRNALys7731 with high and low levels of G7731A mtDNA. 
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Gross necropsy of euthanized moribund mice showed that muscle atrophy (Fig. 3A) and 
anemic kidneys (Fig. 4A) occurred exclusively in mito-mice-tRNALys7731 with high 
levels of G7731A mtDNA. Muscle atrophy occurs not only in elderly men and women 
[16] and patients with mitochondrial diseases [17] but also in mtDNA mutator mice [18, 
19] and mito-mice-Δ that express significant respiration defects [20]. Moreover, renal 
abnormalities have been reported to occur occasionally in patients with mitochondrial 
diseases [21-23] and in mito-mice-Δ that express significant respiration defects [7, 8]. 
We then histologically analyzed these tissues to characterize the macroscopic 
abnormalities in greater detail. First, we used modified Gomori trichrome staining to 
reveal RRFs that occur frequently in patients with mitochondrial diseases [2]. However, 
even aged mito-mice-tRNALys7731 with high levels of G7731A mtDNA lacked RRFs in 
skeletal muscle (Fig. 3B); this was consistent with our recent findings in mtDNA 
mutator mice and mito-mice-Δ [20]. 
Although the skeletal muscle was histologically normal, the anemic kidneys 
demonstrated multiple abnormalities. The renal cortical tubules of aged mito-mice-
tRNALys7731 with high levels of G7731A mtDNA were dilated and contained casts; these 
changes, indicative of renal failures, did not occur in aged B6 mice or in aged mito-
mice-tRNALys7731 with low levels of mutated mtDNA (Fig. 4B). Given that young mito-
mice-tRNALys7731 lacked similar renal changes [12], these changes correspond to a late-
onset disorder. Histologic analysis of mitochondrial respiratory function revealed 
decreased mitochondrial cytochrome c oxidase (COX) activity in the kidney tissue of 
aged mito-mice-tRNALys7731 with high levels of G7731A mtDNA (Fig. 4C). Therefore, 
the respiration defects in mito-mice-tRNALys7731 with high levels of G7731A mtDNA 
(Fig. 4C) likely caused their renal failures (Fig. 4B).  
3.3. Genotyping of G7731A mtDNA in tissues of mito-mice-tRNALys7731 
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For the purposes of this study, we classified 4-week-old mito-mice-tRNALys7731 as 
having low or high amounts of mutated mtDNA by estimating the proportions of 
G7731A mtDNA isolated from samples of tail tissue. The question that then arises is 
whether the proportions of G7731A mtDNA differ among tissues or with age.  
We estimated G7731A mtDNA proportions in various tissues of euthanized moribund 
mito-mice-tRNALys7731. The results showed that, regardless of whether the mouse was 
characterized as having low or high amounts of mutated mtDNA, the proportion of 
G7731A mtDNA in the tail tissue did not differ substantially between samples obtained 
from the same mito-mouse-tRNALys7731 at 4 weeks compared with at 26 to 28 months 
after birth (Fig. S1). Moreover, G7731A mtDNA levels were similar among all tissue 
samples from the same individual mito-mice-tRNALys7731 (Fig. S1).  
  
4. Discussion 
Using mito-mice-tRNALys7731, we showed that high levels of G7731A mtDNA and the 
resultant respiration defects did not affect median survival times (Fig. 2), even though 
they induced the late-onset disorders (Figs. 1, 3 and 4). In contrast, accumulation of 
pathogenic mutations in human mtDNA and the resultant respiration defects have been 
proposed to be responsible for features of normal aging as well as of mitochondrial 
diseases [1–3]. However, our current observations suggest that mtDNA with pathogenic 
mutations is not necessarily associated with aging processes. This idea is further 
supported by our previous findings that mito-mice-COI6589, which contain mtDNA with 
a T6589C mutation in COI, and mito-mice-ND613997, which carry mtDNA with a 
G13997A mutation in ND6, had normal lifespans [11].  
In contrast, our mito-mice-tRNALys7731 developed several phenotypes relevant to 
mitochondrial diseases, including anemia (Fig. 1C), lactic acidosis (Fig. 1D), and 
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increased BUN (Fig. 1E). Moreover, euthanized moribund mito-mice-tRNALys7731 
showed muscle atrophy (Fig. 3A) and renal failures (Fig. 4). The muscle atrophy in 
aged mito-mice-tRNALys7731 with high levels of G7731A mtDNA (Figs. 3A) likely is 
associated with their muscle weakness (Fig. 1B). It is also likely that the anemic kidney 
tissue in the aged mito-mice-tRNALys7731 (Fig. 4A) reflects their low hematocrit levels 
(Fig. 1C). Moreover, the increased BUN values (Fig. 1E) likely reflect the renal failures 
(Fig. 4B) caused by high levels of G7731A mtDNA and the resultant respiration defects 
(Fig. 4C). Given that mito-mice-tRNALys7731 with low and high levels of G7731A 
mtDNA have the same B6 nuclear genetic background, the respiration defects induced 
exclusively by the high levels of G7731A mtDNA are responsible for the development 
of these late-onset disorders.  
A question that then arises is why these abnormalities have a late onset in mito-mice-
tRNALys7731, even though aging did not affect the proportions of G7731A mtDNA in the 
tissues (Fig. S1). One explanation is the requirement of long-term exposure of the 
tissues to respiration defects or the requirement of age-dependent development of 
nuclear abnormalities for the onset of these disorders. It is also likely that each cell in a 
tissue eventually contains solely mtDNA either with or without the G7731A mutation as 
a consequence of stochastic segregation over time [24–26], resulting in the induction of 
the late-onset disorders due to the apoptosis or substantial dysfunction of cells 
containing only G7731A mtDNA. 
In contrast to their other clinically characteristic features, aged mito-mice-tRNALys7731 
with high levels of G7731A mtDNA did not demonstrate peripheral hyperglycemia (Fig. 
1F) indicative of mitochondrial diabetes; this disorder has been proposed to occur 
frequently in patients with mitochondrial diseases [1–3]. However, our results are 
consistent with our previous findings in mito-mice-COI6589, which have normal blood 
glucose levels (9). In addition, blood glucose levels were low in mito-mice-Δ [27] but 
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high in mito-mice-ND613997 [11], indicating that high levels of pathogenic mtDNA 
mutations and the resultant respiration defects do not necessarily cause mitochondrial 
diabetes.  
Current study also showed that all groups of our mice—even aged mito-mice-
tRNALys7731 with high levels of G7731A mtDNA (that is, 70% to 75%)—lacked RRFs 
(Fig. 3B). The absence of RRFs may be due in part to the fact that the amount of 
G7731A mtDNA was insufficient to induce RRFs. Thus, somehow mito-mice-
tRNALys7731 with more than 75% G7731A mtDNA have to be generated for RRF 
development. However, the death of B6 mouse oocytes that carry levels of G7731A 
mtDNA in excess of 85% [12] would prevent the generation of mito-mice-tRNALys7731 
with sufficient proportions of G7731A mtDNA to develop RRFs. It is likely that some 
as-yet unknown nuclear factors in mouse strains other than B6 may allow the survival 
of oocytes with more than 85% G7731A mtDNA.  
To evaluate this idea, we plan to replace the B6 nuclear genetic background of mito-
mice-tRNALys7731 with that from other strains. This replacement may support the 
survival of oocytes with more than 85% G7731A mtDNA and subsequently the 
development of skeletal muscle RRFs and peripheral hyperglycemia in the resultant 
mito-mice-tRNALys7731. 
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Figure legends 
Fig. 1 Mitochondrial disease–related parameters that can be examined without 
euthanizing aged mito-mice-tRNALys7731. Study populations comprised aged B6 mice (n 
= 6) and aged mito-mice-tRNALys7731 with low (less than 5% in tail tissue; n = 4) and 
high (n = 4; 70%, 70%, 72%, and 75% in tail tissue [Fig. S1]) levels of G7731A 
mtDNA in tails at 4 weeks after birth. Disease-related parameters were compared at 26 
months after birth. Intergroup comparison of (A) body length, (B) grip strength, (C) 
hematocrit, (D) blood lactate level, (E) BUN value, and (F) blood glucose level. Data 
are presented as means ± 1 SD. *, P < 0.05; **, P < 0.01. 
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Fig. 2. Kaplan–Meier survival curves of B6 mice (n = 6) and mito-mice-tRNALys7731 
with low (less than 5%; n = 4) and high (70% to 75%; n = 4) levels of G7731A mtDNA. 
Median survival times were 26 months for B6 mice, 28 months for mito-mice-
tRNALys7731 with low levels, and 27 months for mito-mice-tRNALys7731 with high levels.  
Fig. 3. Skeletal muscle abnormalities in aged mito-mice-tRNALys7731. (A) Macroscopic 
evidence of muscle atrophy in the quadriceps of mito-mice-tRNALys7731 with high levels 
of G7731A mtDNA. Scale bar, 5 mm. (B) Histopathologic analysis of skeletal muscles 
to identify RRFs. Cryosections (thickness, 10 µm) of soleus muscle fibers were stained 
by using modified Gomori trichrome to identify RRFs. No RRFs were present even in 
aged mito-mice-tRNALys7731 with high levels of G7731A mtDNA. Scale bar, 50 µm. 
Genotyping of skeletal muscle (soleus) showed that the sample from the low group 
contained 5% G7731A mtDNA, whereas the sample from the high group contained 
65% G7731A mtDNA. 
Fig. 4. Renal abnormalities in aged mito-mice-tRNALys7731. (A) Macroscopic evidence 
of anemic kidneys in mito-mice-tRNALys7731 with high levels of G7731A mtDNA. (B) 
Hemotoxylin and eosin (H&E) staining of formalin-fixed, paraffin-embedded sections 
(thickness, 5 μm) of renal cortex revealed dilated lumens of renal tubules and casts 
(arrowheads) in mito-mice-tRNALys7731 with high levels of G7731A mtDNA. Scale bar, 
50 μm. (C) Histochemical analysis of mitochondrial respiratory enzyme activities in the 
kidney. Tissue sections were stained for COX (brown) and succinate dehydrogenase 
(SDH) (blue). Cells that had lost COX activity were blue because of the absence of 
COX activity. Scale bar, 50 μm. Genotyping of kidney tissue showed that the sample 
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from the low group contained 10% G7731A mtDNA, whereas the sample from the high 
group contained 62% G7731A mtDNA. 
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Supplementary Figure 
Fig. S1. Estimated proportions of G7731A mtDNA in tissue samples from euthanized 
aged (26–28 months) mito-mice-tRNALys7731. 
 
Supplementary Figure Legend 
Fig. S1. Estimated proportions of G7731A mtDNA in tissue samples from euthanized aged (26–28 
months) mito-mice-tRNALys7731. Left, tissues from four mito-mice-tRNALys7731 with low levels of 
G7731A mtDNA; Right, tissues from four mito-mice-tRNALys7731 with high levels of G7731A 
mtDNA. Black bars represent the proportions of G7731A mtDNA estimated from tail tissue samples 
collected at 4 weeks after birth. 
 
